Purchase SDB005
Discount program, second order - 5% OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy SDB005 for sale
SDB-005 is an indazole-based synthetic cannabinoid sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22, where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
SDB-005 is an indazole-based synthetic cannabinoid sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors.
SDB-005, known by its chemical name 1-naphthalene (4-pentyloxynaphthalen-1-yl)-2-(1H-indazol-3-yl)-methanone, is a synthetic cannabinoid that has been sold online as a designer drug for recreational use.
SDB-005 is a synthetic cannabinoid discovered in 2015 and federally banned in the United States in March 2016. The drug is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors.
SDB-005 is an indazole-based synthetic cannabinoid. It can be purchased legally and does not require a prescription. SDB-005 is an analog of PB-22 and MAB-CHMINACA, where the benzene ring has been replaced with an indazole ring.
The code number SDB-005 was originally used for a different compound, the N-phenyl, instead of the N-benzyl analog of SDB-006. This compound is a potent agonist of the CB1 receptor (Ki = 21 nM) and CB2 receptor (Ki = 140 nM).
SDB005 is a synthetic cannabinoid with a benzylnaphthalenone cannabinoid core and a phenethylamine side chain. It is often sold as "legal marijuana" in smoke shops and convenience stores.
SDB005 is a synthetically-manufactured designer drug commonly sold as "legal marijuana" in smoke shops and convenience stores.
SDB005 is an uncontrolled synthetic cannabinoid preparation and an analog of JWH-018.
SDB005 is a designer drug that gives users a euphoric high and alters their mood.
This chemical, SDB-005 (not to be confused with PB-22 or SDB-22), is an indazole-based synthetic cannabinoid sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole analog of PB-22, where the 8-hydroxyquinoline has also been replaced with a naphthalene group. The code number SDB-005 was originally used for a different compound, the N-phenyl, instead of the N-benzyl analog of SDB-006.
SDB005 is an indazole-based synthetic cannabinoid sold online as a designer drug. The code number SDB-005 was originally used for a different compound, the N-phenyl, instead of the N-benzyl analog of SDB-006.
SDB-005 is an indazole-based synthetic cannabinoid sold online as a designer drug. It is presumed to be an agonist of the CB1 and CB2 cannabinoid receptors. SDB-005 is the indazole core analog of PB-22, where the 8-hydroxyquinoline has also been replaced with a naphthalene group.
The code number SDB-005 was originally used for a different compound, the N-phenyl, instead of the N-benzyl analog of SDB-006.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
1kg $1690
1kg $1590
500g $1300
1kg $1590
100g $390
100g $580
1kg $2400
200g $590
100g $490
out of stock
1kg $1590